Search results
AstraZeneca (AZN) Plans to Generate $80B in Revenues by 2030
Zacks via Yahoo Finance· 4 days agoAstraZeneca AZN announced its long-term plan to generate $80 billion in total revenues by 2030,...
AstraZeneca sets sights on $80B in revenue by 2030
BioPharma Dive via Yahoo Finance· 4 days agoA decade ago, as British drugmaker AstraZeneca fought off a hostile takeover bid by Pfizer, CEO Pascal Soriot made a big promise: The company, he said,...
AstraZeneca PLC (NASDAQ:AZN) Shares Acquired by Kingsview Wealth Management LLC
ETF DAILY NEWS· 4 days agoKingsview Wealth Management LLC grew its stake in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 11.3% during the 4th quarter, according to the company in its most recent disclosure ...
AstraZeneca aims for $80 billion in total revenue by 2030 By Reuters
Investing.com· 4 days agoThe Anglo-Swedish drugmaker had reported total revenue of $45.81 billion last year and earlier...
AstraZeneca aims for $80 billion in total revenue by 2030
Reuters via AOL· 5 days agoAstraZeneca aims to grow revenue by about 75% to $80 billion by 2030, it said on Tuesday, boosted by...
AstraZeneca plans to build $1.5 billion manufacturing facility in Singapore
KFGO· 6 days ago(Reuters) -AstraZeneca said on Monday it plans to build a $1.5 billion manufacturing facility in...
Pfizer Wins $107.5M Verdict Against AstraZeneca Over Cancer Drug Patent Dispute
Benzinga· 5 days agoA Delaware federal jury has determined that AstraZeneca Plc AZN must pay Pfizer Inc PFE $107.5...
AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post...
Morningstar· 5 days agoToday AstraZeneca revealed its bold ambition to deliver $80 billion in Total Revenue by 2030, up from $45.8 billion in 2023. This will be achieved through significant growth ...
AstraZeneca to establish $1.5bn ADC production site in Singapore
Pharmaceutical Technology via Yahoo Finance· 4 days agoAstraZeneca is set to invest $1.5bn in a new manufacturing facility in Singapore dedicated to...
SixPeaks, a new obesity biotech, starts up with an option to sell to AstraZeneca
BioPharma Dive via Yahoo Finance· 3 days agoA new obesity drug developer from investment firm Versant Ventures is starting up with a deal to...